Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...